Article Text

P6 Significance of minimal pleural effusion in non-small cell lung cancer
  1. GA Martin1,
  2. S Tsim2,
  3. J MacLay3,
  4. C Stewart1,
  5. KG Blyth1
  1. 1Queen Elizabeth University Hospital, Glasgow, UK
  2. 2Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
  3. 3Glasgow Royal Infirmary, Glasgow, UK


Introduction and objectives Recent publications report a significant survival disadvantage associated with minimal pleural effusion (MiniPE) at presentation of non-small cell lung cancer (NSCLC). MiniPE is defined when an effusion is too small for thoracentesis or where aspiration cytology is negative. Occult pleural metastases (OPM), indirect pathophysiology or comorbidity may cause MiniPE, but staging beyond thoracentesis is rarely performed. Assumption of OPM and therapeutic nihilism may contribute to poor outcomes. We assessed the prognostic impact of MiniPE in potentially radically-treatable NSCLC (Stage I-IIIA), oncologists’ attitudes to treatment planning and the final treatment delivered.

Methods Electronic records and baseline imaging were reviewed retrospectively in 441 consecutive diagnoses of NSCLC made over 6 months in 2009. Stage I-IIIA patients were dichotomized into: No effusion and MiniPE. Malignant effusion (Stage IV) cases were recorded for comparison. The impact of effusion status on overall survival (OS) was estimated using Kaplan-Meier methodology. The probable cause of MiniPE was assessed indirectly using follow-up imaging/records. 3 Clinical Oncologists were surveyed for theoretical treatment plans in 8 randomly-selected MiniPE Stage I-IIIA cases based on anonymised imaging and history. These 24 plans were compared to the treatment delivered in MiniPE patients.

Results 103/441 (23%) patients had MiniPE. 167/441 (38%) were Stage I-IIIA; 26/167 (16%) of these had MiniPE. OS based on effusion status (Stage I-IIIA) is shown in Figure 1. 28/103 (17%) MiniPE patients survived <30 days and had limited post-diagnosis imaging. These were excluded from probable cause analyses. Of the remaining 75/103, 20 (27%) had radiological evidence of progressive pleural malignancy. Radical treatment was delivered in 4/26 (15%) Stage I-IIIA MiniPE cases but advocated in 17/24 (71%) theoretical plans, which showed significant inconsistencies.

Conclusions These retrospective data confirm the negative prognostic impact of MiniPE and suggest the prevalence of OPM is at least 27% in Stage I-IIIA NSCLC. This is likely an underestimate given our limited data in poor prognosis patients. Radical treatment was rarely delivered despite aggressive treatment plans. A prospective study utilising thoracoscopic staging could define the true prevalence of OPM in MiniPE. Objective staging might improve decision-making, radical treatment rates and OS in this context.

Abstract P6 Figure 1

Stage I-IIIA NSCLC Survival by Effusion Status

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.